Mr. Jim Breslin:

On the women who have cervical cancer and who are not in the 221+ group, and Mr. McCallion may wish to add to this, as I set out in my opening statement, some of them will never have been screened and some of them will but they all have cervical cancer. In fairness to the Deputy, he was very active in highlighting that. The most pressing issue was probably access to the drug Pembro with which there was an issue. We have put in place a situation with the HSE where, based on a clinical judgment taken with an individual clinician, there is a route now. If that is decided as the best pathway for a woman, there is a means to address that. I believe that is progress.